Windrose are excited to announce two promotions in our London office. Anjalina Mitra and Agatha Cimbalova have both been promoted to Consultant, after making huge progress in their Senior Analyst roles.

We are pleased to release the next edition of our Windrose Consulting Group: Global News Roundup for Q3 2022.

In this Q&A, we are featuring Jude Baroudi and his career journey and highlights to date.

Windrose Consulting Group are pleased welcome five new starters, Paige Stitzel, Steven Lin, James Fay, Adrian Jung and Ilana Price, into the Philadelphia office.

Windrose Consulting Group are pleased welcome two new starters, Joana Lama and Kristina Funk into the London office.

In an article, published on Pharmexec, Anaïs Frappé, Amy Morgan and Crystal Leung, review market access opportunities in China through private payers, and how Commercial Health Insurance (CHI) can bring value before, during, and after NRDL inclusion.

Windrose are thrilled to announce two key promotions in our London office. Georgina Powell has been promoted to from Senior Analyst to Consultant and Kate Hogan from Senior Consultant to Engagement Manager.

On August 16th, 2022, President Biden signed the Inflation Reduction Act into law, which will bring reforms to Medicare spending and coverage, impacting manufacturers’ long-term P&MA strategy and payer decision-making.

Windrose Consulting Group’s take on The Foreign Data Problem: Implications of the FDA’s New Criteria for Foreign Data Submissions.

We are pleased to release the next edition of our Windrose Consulting Group: Global News Roundup for Q2 2022.

In this Q&A, we are featuring Daisy Pharoah and her career journey and highlights to date.

Last week during the second session of our P&MA strategy course (a collaboration between Windrose and Cambridge University), our guest Andrew Walker produced this nugget:

“Uncertainty has been weaponised by payers”

A global pharmaceutical company was preparing to file a reimbursement dossier for the prevention of migraine in Canada and Europe.

Mark Kohler promoted to Principal and William Noumba Um to Senior Analyst at Windrose Consulting Group.

On Friday, April 22nd, 2022, Biogen announced that it had withdrawn the marketing application in the EU for aducanumab (Aduhelm), its monoclonal antibody that targets aggregated forms of amyloid beta found in the brains of Alzheimer’s patients.

Our client had recently received EMA approval for a novel androgen receptor inhibitor, indicated within several solid tumors.

We are pleased to release the second edition of our Windrose Consulting Group: Global News Roundup for Q1 2022.

Our client had a Phase III biosimilar for the treatment of febrile neutropenia in the pipeline, with an estimated 5-years to launch

Our client had a late-stage vaccine candidate targeting older adult (OA) respiratory syncytial virus (RSV), and wanted support with its US pricing and access strategy.

The application of biomarkers in therapy areas beyond oncology will likely play an ever-crucial role in developing more targeted therapies in high unmet need indications, while providing payers with new attributes by which to assess a new treatment’s value.